Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer

Long non-coding RNAs (lncRNAs) are a group of non-coding transcripts of more than 200 nucleotides that play important biological and clinical roles in prostate cancer (PCa) tumorigenesis, progression and metastasis. They have also shown potential as a biomarker in the diagnosis and prognosis of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghiam, Alireza Fotouhi, Vesprini, Danny, Liu, Stanley K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422697/
https://www.ncbi.nlm.nih.gov/pubmed/28540248
http://dx.doi.org/10.21037/tau.2017.03.06
Descripción
Sumario:Long non-coding RNAs (lncRNAs) are a group of non-coding transcripts of more than 200 nucleotides that play important biological and clinical roles in prostate cancer (PCa) tumorigenesis, progression and metastasis. They have also shown potential as a biomarker in the diagnosis and prognosis of this disease. LncRNA prostate cancer associated transcript-14 (PCAT-14) was recently identified as a novel prognostic biomarker in PCa, whose low expression was associated with poor outcomes. Here, we briefly discuss future perspectives and clinical applications of lncRNAs as biomarkers and therapeutic targets for PCa.

Ejemplares similares